Plain-English translation of NCT06296706 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a newer form of a chemotherapy drug called to treat advanced stomach cancer. Researchers want to compare this new formulation with the older, standard version of the same drug to see if it works better, is easier to tolerate, or has fewer side effects. About 630 patients will be randomly assigned to receive one form or the other.
Stomach cancer that has spread or grown despite initial chemotherapy treatment is very difficult to treat, and doctors need better options. This medication may help, but researchers want to know if the newer formulation is more effective or safer than the version currently used.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you enroll, you will be randomly assigned to receive one of the two forms of the medication as an intravenous infusion (through an IV) once every 3 weeks. You will continue treatment until your cancer stops responding or you experience unacceptable side effects. Throughout the trial, you will have regular clinic visits and imaging scans (such as CT scans) to check how your cancer is responding and to monitor for any side effects.
AI-generated summary from trial data ยท Jun 4, 2026 ยท Not medical advice
China
Phase
Large-scale testing
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Enrollment target
~630 participants
Started
February 2024
Primary completion
June 2026
This trial's estimated completion date has passed โ the record may not be fully up to date.
Age range
18 Years โ 75 Years
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Clinical Trials Information Group officer
Sun Yat-sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.